Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat CIO in H2 2021. The Company also expects to start a natural history clinical study in CIO in adult cancer patients in H1 2021.

“SENS-401 has demonstrated highly encouraging efficacy in preclinical models and we are excited to progress this small molecule towards clinical trials to address this significant unmet medical need in cancer patients undergoing cisplatin treatment. Hearing loss caused by this chemotherapeutic treatment leads to permanent inner ear problems in 50-60% of cases, significantly impacting patients’ quality of life¹. We look forward to further investigating the potential of SENS-401 to prevent this life-altering condition” says Géraldine Honnet, Chief Medical Officer of Sensorion.

An estimated 500,000 people will suffer from CIO in G7 countries by 2025 causing hearing loss, tinnitus and dizziness². A critical requirement of any potential treatment for CIO is that it should not interfere with the efficacy of cisplatin, a potential differentiating feature of SENS-401. The natural history study will generate data on the course of hearing loss from CIO and contribute to the recruitment for the clinical study. Further details on the trial design will be communicated in H2 2021.

SENS-401 is a 5-HT3 receptor antagonist and calcineurin inhibitor which has been shown to siginificantly reduce hearing loss from CIO in preclinical models³. The use of SENS-401 has led to the survival of substantially more outer hair cells compared to placebo. Outer hair cells are the most vulnerable sensory cells in the inner ear which help amplify sound signals to increase hearing sensitivity. SENS-401 is also in Phase 2 development for the treatment of Sudden Sensorineural Hearing Loss (SSNHL).

Due to the impact of COVID-19, including the reinitiation of strict lockdown measures in some of the countries involved, Sensorion now expects a further delay in the availability of topline results from the Phase 2 study of SENS-401 in SSNHL. Topline data are now anticipated in Q4 2021 rather than mid-2021 as had been previously estimated. Sensorion continues to review this study and consider opportunities which could aid in its successful completion despite the challenges provided by COVID-19 and its knock-on effects.